

Adagio Medical Holdings, Inc. (ADGM)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0002006986

Adagio Medical Holdings, Inc.		
ADGM; healthcare		
Grade	None 6 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$43.3M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, short runway, thin data, degenerate inputs not computable: distress	
Inputs computable	6 of 14	
Graded from	filings received through Jul 13, 2026 88 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026	
Last close	\$0.13 2026-10-08; market equity \$2.9M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

We are a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with our novel, proprietary, catheter-based Ultra-Low Temperature Ablation ("ULTA") technology, formerly known as Ultra-Low Temperature Cryoablation ("ULTC") technology. Our initial focus is on the treatment of ventricular tachycardia ("VT"). VT is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, VT can be fatal. In the United States, VT-associated sudden cardiac death ("SCD") accounts for approximately 300,000 deaths each year.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 74.5						
Gross profitability	— + + + + + ■	(1.6%)	32.2%	98.4	372	2025-12-31
Return on invested capital	— + + + + + ■	(133.3%)	9.3%	91.8	74	2025-12-31
Accruals ratio	— + ■ + + + +	(13.2%)	(6.6%)	33.3	811	2025-12-31

Gross margin stability, five years	not computable	2.8 pts				five annual gross margins are required; found 1
Solvency, sleeve percentile 61.8						
Twelve-month failure probability	not computable	0.07%				latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(8.39)	(0.31)	59.2	756	2025-12-31
Net debt to EBITDA	not computable	1.82x				EBITDA must exceed \$100,000
Interest coverage	not computable	(4.51x)				one or more required annual facts are missing
Current ratio		2.44x	2.96x	64.3	839	2025-12-31
Growth and financing, sleeve percentile 74.7						
Revenue growth, three-year compound	not computable	10.0%				four annual observations are required; found 1
Free cash flow growth, three-year compound	not computable	10.9%				four consecutive annual FCF observations are required; found 1
Reinvestment rate	not computable	37.1%				NOPAT must exceed \$100,000
Asset growth, three years	not computable	2.1%				four annual observations are required; found 2
Net share issuance, one year		44.4%	2.5%	74.7	634	2026-03-23

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 44.4%
Short runway	cash runway is 5.6 months
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(72.8%)	8.0%	6
Distance from 52-week high	(94.5%)	(31.4%)	3
EBIT to enterprise value	(109.5%)	(1.5%)	6
Free cash flow yield	(671.5%)	(1.0%)	1

Book value to price	(0.14)	0.28	6
Sales to price	0.00	0.31	0
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(1.51)	(0.14)	6

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$7.7M
Operating cash flow, four quarters	-\$16.5M
Months of runway	5.6
Days since last periodic filing	59 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	\$147,850

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2025-12-31	2026-03-27	10-K	0002006986-26-000003
2	cost of revenue	us-gaap:CostOfRevenue	\$684,000	2025-12-31	2026-03-27	10-K	0002006986-26-000003
3	assets	us-gaap:Assets	\$43.3M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
4	operating income	us-gaap:OperatingIncomeLoss	-\$21.9M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$15.3M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-03-27	10-K	0002006986-26-000003
7	total debt	us-gaap:LongTermDebt	\$21.0M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
8	book equity	us-gaap:StockholdersEquity	\$12.4M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$17.1M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
10	total debt	us-gaap:LongTermDebt	\$17.2M	2024-12-31	2026-03-27	10-K	0002006986-26-000003
11	book equity	us-gaap:StockholdersEquity	\$19.9M	2024-12-31	2026-03-27	10-K	0002006986-26-000003
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$20.6M	2024-12-31	2026-03-27	10-K	0002006986-26-000003
13	net income	us-gaap:NetIncomeLoss	-\$25.1M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$19.0M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
15	assets	us-gaap:Assets	\$48.4M	2024-12-31	2026-03-27	10-K	0002006986-26-000003
16	current assets	us-gaap:AssetsCurrent	\$20.1M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
17	current liabilities	us-gaap:LiabilitiesCurrent	\$8.2M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$95.6M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
19	liabilities	us-gaap:Liabilities	\$30.9M	2025-12-31	2026-03-27	10-K	0002006986-26-000003
20	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$970,000	2025-12-31	2026-03-27	10-K	0002006986-26-000003
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$374,000	2025-12-31	2026-03-27	10-K	0002006986-26-000003
22	current assets	us-gaap:AssetsCurrent	\$25.3M	2024-12-31	2026-03-27	10-K	0002006986-26-000003
23	current liabilities	us-gaap:LiabilitiesCurrent	\$7.8M	2024-12-31	2026-03-27	10-K	0002006986-26-000003
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	22,210,459	2026-03-23	2026-07-13	10-K/A	0001104659-26-082769
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	15,381,565	2025-04-23	2025-04-30	10-K/A	0001410578-25-001044